PP405 shows promise for hairfollicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
Caffeine may promote hair growth and potentially inhibit 5-α-reductase activity in hairfollicles, but its effectiveness and systemic impact remain unclear. Users discuss using topical caffeine solutions, with some experiencing no side effects compared to finasteride.
PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.
PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.
Hair loss may be caused by calcification of capillaries in the scalp, restricting blood flow to hairfollicles. A daily treatment regimen including high doses of Vitamins D and K, Magnesium, and Nattokinase could potentially decalcify these capillaries, improving blood flow and hair growth. However, some users warn against excessive Vitamin D intake and emphasize the need for medical consultation.
Hair loss treatment should target dermal white adipose tissue (DWAT) to restore hairfollicles. Potential remedies include tocopherol (vitamin E), botox, rosiglitazone, niacin, kojyl cinnamate esters, and ADP355.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hairfollicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
PP405 is a potential hair loss treatment that may activate dormant hairfollicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.
Pelage is developing a topical hairfollicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.
PP405 is a promising new hair loss treatment that may reactivate dormant hairfollicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
Hair loss treatments like Minoxidil, finasteride, and stem cell therapies exist, but a complete cure is hindered by genetic complexity and market dynamics. Cloning hairfollicles is considered a potential solution, but it's currently not feasible.
Accutane may accelerate hair loss in genetically predisposed individuals by affecting enzymes related to DHT metabolism. Some users report hair loss after taking Accutane, while others use treatments like finasteride and minoxidil to manage hair loss.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hairfollicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
Minoxidil's effectiveness is limited by the need for sulfation and proper transport to hairfollicles, with tretinoin potentially enhancing its effects by promoting enzyme activity and keratinocyte differentiation. Tretinoin may improve minoxidil's response by boosting the expression of necessary enzymes and transporters.
PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hairfollicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hairfollicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hairfollicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hairfollicles to androgens.
User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hairfollicles for better treatment.
First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hairfollicles, potentially reducing side effects.
The user has been experiencing prolonged hair shedding despite using Dutasteride, Minoxidil, and topical Finasteride, with blood tests showing high free testosterone and low SHBG. Suggestions include adjusting Minoxidil dosage, considering topical anti-androgens like RU58841, and addressing metabolic factors to increase SHBG.
PP405 may not need daily use like minoxidil, but finasteride might still be needed to maintain hair regrowth. PP405 reawakens dormant hairfollicles, potentially offering a long-term solution, though not a permanent cure.
The conversation discusses whether finasteride's reduction of DHT and increase in scalp testosterone contribute to hairfollicle miniaturization. Some participants argue testosterone does not cause miniaturization, while others suggest that even with reduced DHT, other androgens like testosterone may still contribute to hair loss.
The conversation is about the effects of steroids on hair loss. Some users believe that steroids can cause hair loss, while others argue that it depends on individual sensitivity to DHT. There is also discussion about the appearance of balding individuals who use steroids.
Sugary beverages increase the risk of pattern hair loss in men by 57%, and type 2 diabetes is linked to female pattern hair loss. Reducing sugar intake and using treatments like finasteride and minoxidil may help manage hair loss.
Hair loss treatments include topical and oral minoxidil, low-level laser light therapy, and peptide serums. Bryan Johnson avoids finasteride and dutasteride due to potential side effects, focusing instead on his own protocol with these treatments.
Excess sebum rich in cholesterol and triglycerides can lead to hair loss through inflammation, with treatments like Ciclopirox shampoo, Benzoyl Peroxide shampoo, and Clindamycin gel recommended for managing conditions like seborrheic dermatitis and folliculitis. Pioglitazone is suggested for Lichen Planopilaris, while Omega-3s and reducing processed foods may improve sebum quality, though genetic factors play a significant role.
COVID and COVID vaccination can trigger hair loss, primarily telogen effluvium, due to stress and immune system activation. Proper diagnosis and addressing factors like nutrition and stress are crucial for recovery.